HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Cocrystal Pharma (NASDAQ:COCP) and maintained a $12 price target.
October 04, 2023 | 10:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cocrystal Pharma's stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating and a $12 price target.
Analyst ratings and price targets can significantly influence a stock's performance. The reiteration of a 'Buy' rating and a maintained price target of $12 by HC Wainwright & Co. suggests a positive outlook for Cocrystal Pharma, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100